Scientific programming language

Implantica's RefluxStop™ makes an impact at the leading Annual European Foregut Society Meeting

Retrieved on: 
Wednesday, November 15, 2023
Associate, EFS, GERD, Surgeon, Teaching hospital, Patient, CET, ARB, Scientific programming language, Humble, Texas, GI, Certification, Congress, Quality of life, Deutsche Medizinische Wochenschrift, Health

), a medtech company at the forefront of bringing advanced technology into the body, announces participation in the 3rd Annual EFS (European Foregut Society) Congress in Milan, Italy in early November.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces participation in the 3rd Annual EFS (European Foregut Society) Congress in Milan, Italy in early November.
  • The Scientific Program at EFS included the symposium, 'Reconstruction of the Anti-Reflux Barrier (ARB) with RefluxStop™- an innovative approach.'
  • This well-attended event, filled with lively conversation, offered an opportunity to learn directly from experts with real-world experience performing the RefluxStop™ procedure.
  • Dr. Forsell goes on to say, "The 3rd Annual EFS Meeting gave Implantica the opportunity to spotlight RefluxStop™ and report on the excellent clinical data.

Global Genes' RARE-X Names Winners to the Xcelerate RARE Open Science Data Challenge

Retrieved on: 
Wednesday, September 20, 2023
Sage Bionetworks, Analytics, Roche, St. Jude Children's Research Hospital, Xcelerator, Research, Rare, Scientific programming language, Global Genes, Patent, Machine learning, SAN, Data, Algorithm, RTW, Gene, Challenge, Diagnosis, Hospital, Ecosystem, AI, Team, Cord, Disease, Pharmaceutical industry, Medical device, Datavant

SAN DIEGO, Sept. 20, 2023 /PRNewswire-PRWeb/ -- The rare patient advocacy organization Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.

Key Points: 
  • Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.
  • The Xcelerate RARE Challenge brought together academic and industry researchers and data scientists to use patient-reported data for rare pediatric neurodevelopmental diseases to address unanswered research questions about rare diseases.
  • SAN DIEGO, Sept. 20, 2023 /PRNewswire-PRWeb/ -- The rare patient advocacy organization Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.
  • The Xcelerate RARE Challenge, which was focused on rare pediatric neurodevelopmental diseases, brought together academic and industry researchers and data scientists to use patient-reported data to address unanswered research questions about rare diseases.

Randall C. Starling, MD, MPH Receives 2023 HFSA Lifetime Achievement Award for His Contributions to the Field of Heart Failure

Retrieved on: 
Thursday, September 14, 2023
Cleveland Clinic, Vice, University, Alpha and Omega, Heart failure, Education, Internal medicine, Temple University, Heart Failure Society of America, Lung transplantation, NIH, American College of Cardiology, Case Western Reserve University, Research, Journal of Cardiac Failure, Alpha Omega Alpha, National Institutes of Health, Associate, Bangladesh Technical Education Board, Science, OSU, University of Pittsburgh Medical Center, Public health, Journal, Publishing, Overmyer Network, Scientific programming language, Cardiology, Huntington Convention Center of Cleveland, Master, Biology, American College, MPH, Wilfrid Sellars, International Society, Medical device, Dentistry, MD, Medicine

The award will be presented to Dr. Starling at the HFSA Annual Scientific Meeting on Saturday, October 7 in Cleveland, Ohio.

Key Points: 
  • The award will be presented to Dr. Starling at the HFSA Annual Scientific Meeting on Saturday, October 7 in Cleveland, Ohio.
  • As an internationally recognized pioneer and expert in the field of heart failure, this prestigious award will pay tribute to his exemplary career in heart failure research, publishing, mentorship and leadership.
  • Dr. Starling served as President of HFSA in 2018-2019 and has been an active member since its inception in 1995.
  • Dr. Starling joins an elite list of current and past Lifetime Achievement Award winners with this year's recognition.

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Pancreatic cancer, Abstract, Partnership, University, Therapy, Breast, Treatment of lung cancer, Scientific programming language, PDX, ASCO, RAS, Cancer, Annual general meeting, University of Louisville School of Medicine, UofL, Poster, Society, Pharmaceutical industry

CARLSBAD, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that a poster featuring the Company’s pan-RAS inhibitor program in pancreatic cancer will be presented as part of the Scientific Program at the American Society of Clinical Oncology’s (ASCO) 2023 Annual Meeting held June 2-6, 2023 in Chicago.

Key Points: 
  • The Company had two abstracts accepted to the meeting, the other of which is “ A novel pan-RAS inhibitor for luminal B breast cancer .
  • This abstract can be found in the ASCO 2023 Annual Meeting Abstract Book.
  • Qualigen’s pan-RAS inhibitor platform is a family of small molecules designed to prevent mutated RAS gene proteins from binding to their effector proteins.
  • Qualigen is evaluating promising compounds generated from this partnership in various RAS-driven advanced solid tumors such as pancreatic, breast, colorectal, and lung cancers.

Global Genes' RARE-X Issues Open Call to Researchers to Participate in the Inaugural Xcelerate RARE Challenge

Retrieved on: 
Wednesday, May 31, 2023
Sage Bionetworks, Roche, Quality of life, Xcelerator, Research, Scientific programming language, Global Genes, Patient, CACNA1A, Machine learning, Algorithm, RTW, Challenge, RARE, Disease, Pharmaceutical industry

ALISO VIEJO, Calif., May 31, 2023 /PRNewswire-PRWeb/ -- Global Genes today announced an open call to researchers interested in participating in its inaugural Xcelerate RARE Challenge, a rare disease open science challenge focused on rare pediatric neurodevelopmental diseases.

Key Points: 
  • ALISO VIEJO, Calif., May 31, 2023 /PRNewswire-PRWeb/ -- Global Genes today announced an open call to researchers interested in participating in its inaugural Xcelerate RARE Challenge, a rare disease open science challenge focused on rare pediatric neurodevelopmental diseases.
  • The Xcelerate RARE Challenge brings together academic and biopharmaceutical industry researchers and data scientists to use patient reported data to address unanswered research questions about rare diseases.
  • "With this Xcelerate RARE Challenge, our goal is to advance rare disease understanding and meaningful therapeutic research for rare diseases through open sharing of robust data, and collaboration."
  • Without the generosity and unwavering support of the sponsors and partners, the Xcelerate RARE Challenge would not have been possible.

ISHLT Annual Meeting & Scientific Sessions to Convene International Transplant Community Next Month

Retrieved on: 
Tuesday, March 14, 2023
Online, International Society for Heart and Lung Transplantation, Research, Heart, Society, Ethics, Annual general meeting, Grant, Convention, Cardiogenic shock, Abstract, CO, Symposia, Scientific programming language, Lung transplantation, Patient, Science, APN, CME, Health equity, FAAN, DCD, CAE, International Society, CMV, Doctor of Philosophy, Continuing medical education, Lung, Dentistry, MD

Chicago, IL, March 14, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) will host its 43rd Annual Meeting & Scientific Sessions on 19-22 April, 2023 in Denver, CO USA.

Key Points: 
  • Chicago, IL, March 14, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) will host its 43rd Annual Meeting & Scientific Sessions on 19-22 April, 2023 in Denver, CO USA.
  • “Over the past year, the Annual Meeting Program Planning Committee was hard at work developing a highly innovative, exciting, and educational Scientific Program,” said Howard Eisen, MD, ISHLT 2023 Scientific Program Chair.
  • As the flagship meeting of this community, the ISHLT Annual Meeting has something for everyone on the entire care team and is the gateway to the latest scientific advances.
  • “The ISHLT Annual Meeting is the focal point for ISHLT members and others who care for patients with advanced heart and lung disease, and the centerpiece of the ISHLT year,” said Greg Schultz, CAE, ISHLT CEO.

NUROSENE ANNOUNCES ADVISORY ROLE WITH RARE-X

Retrieved on: 
Wednesday, January 18, 2023
Disease, Open science, Advisory board, Roche, Scientific programming language, OTC, CSE, FSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Global Genes, Machine learning, Hope, Food, Degenerative disease, Patient, Research, Artificial intelligence, Xcelerator, RTW, Pharmaceutical industry

"I am pleased to announce that NetraMark has agreed to an advisory role with RARE-X.

Key Points: 
  • "I am pleased to announce that NetraMark has agreed to an advisory role with RARE-X.
  • As part of the relationship, Dr. Joseph Geraci will join RARE-X's Advisory Board for Xcelerate RARE: An Open Science Data Challenge and RARE-X will provide NetraMark access to their world class rare disease data sets."
  • Core to this advisory role is the RARE-X Open Science Data Challenge which brings together industry leaders, such as the RTW Charitable Foundation, Roche, the Alliance for Artificial Intelligence in Healthcare and includes expert advice from the U.S. Food and Drug Administration, as sited at https://rare-x.org/open-science-data-challenge/ .
  • "We are thrilled that Netramark is partnering with us in this Open Science Data Challenge," said Karmen Trzupek, Senior Director of Scientific Programs for Global Genes.

RARE-X to Launch an Open Science Data Challenge to Address Rare Neurodevelopmental Diseases

Retrieved on: 
Tuesday, January 17, 2023
Disease, Roche, Algorithm, Scientific programming language, Communication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Global Genes, Machine learning, Prom, Patient, Diagnosis, Food, Research, Artificial intelligence, Open science data, Xcelerator, RTW, Sage Bionetworks, Pharmaceutical industry

ALISO VIEJO, Calif., Jan. 17, 2023 /PRNewswire-PRWeb/ -- RARE-X, the Global Genes collaborative platform for rare disease patients to share their data to accelerate the development of diagnoses and treatments, today announced its inaugural Xcelerate RARE: An Open Science Data Challenge to bring together researchers and data scientists to use patient-provided data to address unanswered research questions about rare diseases.

Key Points: 
  • The first Xcelerate RARE challenge will launch in the spring of 2023 and will focus on rare pediatric neurodevelopmental diseases.
  • ALISO VIEJO, Calif., Jan. 17, 2023 /PRNewswire-PRWeb/ -- RARE-X, the Global Genes collaborative platform for rare disease patients to share their data to accelerate the development of diagnoses and treatments, today announced its inaugural Xcelerate RARE: An Open Science Data Challenge to bring together researchers and data scientists to use patient-provided data to address unanswered research questions about rare diseases.
  • "The Open Science Data Challenge is like a long-form hackathon," said Karmen Trzupek, Senior Director of Scientific Programs for Global Genes.
  • Or listen to the RARE-Xtra Podcast on An Open Science Data Challenge to Address Rare Neurodevelopment Diseases.

Bertis Announces Research Results of AI-based Disease Diagnosis Model in the World’s Largest Academic Event in Proteomics

Retrieved on: 
Thursday, December 8, 2022
Research, Technology, Engineering, Manufacturing, Biotechnology, Health, Data Management, Science, Oncology, Artificial Intelligence, Ovarian cancer, Korean Intellectual Property Office, Multiomics, SAME, Ministry of Food and Drug Safety, Spectrum, Software, MFDS, Diagnosis, Plasma, Korean Ministry of Culture, PASS, Patient, Biomarker, Cancer, Ministry, AND, Mass spectrometry, Research, Precision medicine, NET, Breast cancer, Scientific programming language, Disease, Deep learning, Medicine, AI, Proteome, MOTIE, Guideline, Khidi-Khutor, Multimedia, Marketing, Proteomics, Health, Machine learning, HUPO, Pancreatic cancer, Patent, Algorithm, Medical device, Medical imaging, Food, Bertie the Brain, SAN

Bertis , a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis model, on December 8, 2022, at Human Proteome Organization 2022 (HUPO 2022), the worlds largest academic event in the field of proteomics1.

Key Points: 
  • Bertis , a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis model, on December 8, 2022, at Human Proteome Organization 2022 (HUPO 2022), the worlds largest academic event in the field of proteomics1.
  • According to the results of its research, Bertis developed a diagnosis model that can determine the presence of a disease solely with proteomic mass spectrometry data by applying deep learning-based AI technology.
  • View the full release here: https://www.businesswire.com/news/home/20221208005409/en/
    Eric Y. Kim, Principal Machine Learning Engineer of Bertis Bioscience, is sharing the research results of a deep learning-based disease diagnosis model.
  • Bertis deep learning model uses only the proteomic spectrum to determine the existence of ovarian and pancreatic cancer with over 95% accuracy.

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

Retrieved on: 
Thursday, October 27, 2022
Nexus, MND, International Symposium on Endovascular Therapy, IP, NASDAQ, Goal, AI, Society, Nature, Annual general meeting, Forward-looking statement, Neuroscience, Disease, Technology, Therapy, Patient, Phase, Partnership, Motor neuron disease, PWN, Research, Poster, Hot Topic, Parkinson's disease, Peace committee, Biomarker, Neurodegeneration, SFN, Society for Neuroscience, ALS, Amyotrophic lateral sclerosis, Alzheimer's disease, Pangborn Sensory Science Symposium, Scientific programming language, Pharmaceutical industry, Medical device, Science

CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences.
  • Dr. Shiran Zimri, NeuroSense's Head of Scientific Program, will present a poster on NeuroSense's recent biomarker research, developments, and findings.
  • Dr. Niva Russek-Blum, NeuroSense' VP Discovery & IP Generator, will also attend the conference, exploring potential scientific collaborations and partnership opportunities.
  • NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.